Cerecor is a clinical-stage biopharmaceutical company, which develops drugs to treat patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Gross profit (Q1, 2019)
Gross profit margin (Q1, 2019), %
Net income (Q1, 2019)
EBIT (Q1, 2019)
Market capitalization (10-Jun-2019)
Closing stock price (10-Jun-2019)
|USD||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017||Q2, 2017||Q3, 2017||Q1, 2018||Q2, 2018||Q3, 2018||Q1, 2019|
Depreciation and Amortization
Cash From Operating Activities
|Acquired Company||Date||Deal Size|
|Ichorion Therapeutics||September 28, 2018||$27 m|
When was Cerecor founded?
Cerecor was founded in 2011.
Who are Cerecor key executives?
Cerecor's key executives are Peter Greenleaf, Matthew V. Phillips and Perry Calias.
How many employees does Cerecor have?
Cerecor has 64 employees.
What is Cerecor revenue?
Latest Cerecor annual revenue is $18.3 m.
What is Cerecor revenue per employee?
Latest Cerecor revenue per employee is $286.4 k.
Who are Cerecor competitors?
Competitors of Cerecor include Opiant Pharmaceuticals, Mylan and Amphastar Pharmaceuticals.
Where is Cerecor headquarters?
Cerecor headquarters is located at 400 E Pratt St #606, Baltimore.
Where are Cerecor offices?
Cerecor has an office in Baltimore.
How many offices does Cerecor have?
Cerecor has 1 office.
Receive alerts for 300+ data fields across thousands of companies